Skip to main content
SHELTER PHARMA LIMITED logo

SHELTER PHARMA LIMITED — Investor Relations & Filings

Ticker · 543963 ISIN · INE013V01011 BSE.NS Manufacturing
Open in API
Filings indexed 11 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country IN India
Listing BSE.NS 543963

About SHELTER PHARMA LIMITED

https://shelter.co.in/

Shelter Pharma Limited specializes in the research, development, and manufacture of Ayurvedic and herbal formulations. The company’s product portfolio is divided into human and veterinary healthcare segments. The human healthcare division focuses on natural remedies for gastrointestinal issues, liver health, skin care, and respiratory conditions, utilizing traditional botanical ingredients. In the veterinary sector, the company provides herbal supplements aimed at enhancing livestock productivity, including growth promoters and lactation stimulants. Shelter Pharma integrates traditional Ayurvedic knowledge with contemporary manufacturing processes to produce standardized herbal medicines in various dosage forms such as tablets, syrups, and topicals. The company prioritizes the development of side-effect-free, natural alternatives to synthetic pharmaceuticals, targeting diverse therapeutic areas for both domestic and international markets.

Recent filings

Filing Released Lang Actions
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015- Receipt of Renewal Manufacturing Licence
Regulatory Filings Classification · 90% confidence The document is a short SEBI LODR Regulation 30 intimation regarding receipt of a renewal manufacturing license. It does not contain financial statements, management discussion, or details of a report itself, but rather is a regulatory compliance announcement. This falls under the general "Regulatory Filings (RNS)" category.
2026-06-02 English
Statement of Deviation or Variation pursuant to Regulation 32 of SEBI ( Listing Obligations and Disclosure Requirements) Regulatioms 2015
Regulatory Filings Classification · 76% confidence The document is a regulatory‐mandated “Statement of Deviation or Variation” under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulation 32), confirming no variation in the use of preferential issue proceeds. It is not announcing a vote, dividend, or presenting full financial statements, nor is it the full financial report itself. It is a continuous disclosure filing required by the stock exchange. Therefore, it falls under Regulatory Filings (RNS).
2026-05-28 English
Outcome of the board meeting and submission of the audited standalone finaacial results for the half year and year ended march 31, 2026 and appointment of internal auditor.
Interim / Quarterly Report Classification · 78% confidence The document is a formal filing under SEBI LODR Regulation 33 reporting the Board’s approval and submission of audited standalone financial results for the half year and full year ended March 31, 2026. It includes the auditor’s report with unmodified opinion and detailed profit & loss statement (actual substantive financial data), not merely an announcement or summary. This aligns with the definition of an Interim/Quarterly Report (IR) for periods shorter than a full fiscal year (in this case a half-year) and contains substantive financial statements rather than a simple earnings release. FY 2026
2026-05-28 English
Outcome of the Board Meeting and Submission of the Audited Standalone Financial Results for the Half year and year ended March 31, 2026.
Interim / Quarterly Report Classification · 87% confidence The document is the outcome of a board meeting under SEBI LODR regulations, enclosing detailed standalone audited financial results (including P&L statements) for the half year and year ended March 31, 2026, along with the auditor’s report. It contains full financial statements and substantive data for a period shorter than a full fiscal year (half-year results). It is not merely an earnings highlights release or a brief announcement but a comprehensive interim financial report. Therefore, it should be classified as an Interim/Quarterly Report (IR). FY 2026
2026-05-28 English
Outcome of the Board Meeting and Submission of the Audited Standalone Financial Results for the Half year and year ended March 31, 2026.
Interim / Quarterly Report Classification · 90% confidence The document is a SEBI (LODR) Regulation 33 submission to the stock exchange providing the Board-approved standalone audited financial results for the half‐year and year ended March 31, 2026, complete with detailed profit & loss statements and an independent auditor’s report. It contains full financial statements, not merely highlights or a link to a report. This fits the definition of an Interim/Quarterly Report (IR) since it covers a period shorter than a full fiscal year and includes substantive financial data and auditor opinions. FY 2026
2026-05-28 English
Shelter Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....
Regulatory Filings Classification · 85% confidence The document is a formal intimation under Regulation 29 of SEBI LODR notifying the stock exchange of an upcoming Board of Directors meeting to consider audited financial results. It does not contain actual financial statements or an earnings announcement, nor is it a change in management. It is a regulatory announcement of a board meeting date and agenda items, thus falling under Regulatory Filings (RNS).
2026-05-22 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.